[go: up one dir, main page]

PE20141152A1 - Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana - Google Patents

Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana

Info

Publication number
PE20141152A1
PE20141152A1 PE2013001719A PE2013001719A PE20141152A1 PE 20141152 A1 PE20141152 A1 PE 20141152A1 PE 2013001719 A PE2013001719 A PE 2013001719A PE 2013001719 A PE2013001719 A PE 2013001719A PE 20141152 A1 PE20141152 A1 PE 20141152A1
Authority
PE
Peru
Prior art keywords
triterpenoids
maturation
modified
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
PE2013001719A
Other languages
English (en)
Inventor
Alicia Regueiro-Ren
Zheng Liu
Jacob Swidorski
Ny Sin
Brian Lee Venables
Sing-Yuen Sit
Yan Chen
Jie Chen
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20141152A1 publication Critical patent/PE20141152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO QUE INCLUYE SALES DE ESTE FARMACEUTICAMENTE ACEPTABLES, SELECCIONADO DEL GRUPO DE COMPUESTOS DE FORMULA I, FORMULA II Y FORMULA III, DONDE R1 ES ISOPROPENILO O ISOPROPILO; J Y E SON H O CH3, E ESTA AUSENTE CUANDO EL ENLACE DOBLE ESTA PRESENTE; X ES FENILO O HETEROARILO SUSTITUIDO CON A, A ES H, HALO, HIDROXILO, ENTRE OTROS; Y ES TETRAZOL, -CONHOH, ENTRE OTROS; R4 ES H, ALQUILO C1-6, ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, ALQUILO C1-6, CICLOALQUILO C3-6, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL VIH, SIENDO UTILES PARA EL TRATAMIENTO DEL VIH Y SIDA
PE2013001719A 2011-01-31 2012-01-27 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana PE20141152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31

Publications (1)

Publication Number Publication Date
PE20141152A1 true PE20141152A1 (es) 2014-09-22

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001719A PE20141152A1 (es) 2011-01-31 2012-01-27 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana

Country Status (25)

Country Link
US (3) US8846647B2 (es)
EP (1) EP2670765B1 (es)
JP (1) JP6001560B2 (es)
KR (1) KR101886467B1 (es)
CN (1) CN103429607B (es)
AR (1) AR085053A1 (es)
AU (1) AU2012212509B2 (es)
BR (1) BR112013019419A2 (es)
CA (1) CA2826113C (es)
CL (1) CL2013002185A1 (es)
CO (1) CO6751275A2 (es)
EA (1) EA022470B1 (es)
ES (1) ES2653847T3 (es)
IL (1) IL227678B (es)
MA (1) MA34909B1 (es)
MY (1) MY162186A (es)
PE (1) PE20141152A1 (es)
PH (1) PH12013501528A1 (es)
PT (1) PT2670765T (es)
SG (1) SG192144A1 (es)
TN (1) TN2013000321A1 (es)
TW (1) TWI628188B (es)
UY (1) UY33886A (es)
WO (1) WO2012106190A1 (es)
ZA (1) ZA201306546B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
RS55631B1 (sr) 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP2670764B1 (en) * 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
PL2683731T3 (pl) 2011-03-11 2019-09-30 Reata Pharmaceuticals, Inc. C4-monometylowe pochodne triterpenoidów i sposoby ich zastosowania
JP6100786B2 (ja) 2011-09-21 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ウイルス活性を有する新規ベツリン酸誘導体
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013163344A1 (en) 2012-04-27 2013-10-31 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
CN104619706B (zh) * 2012-08-15 2017-06-20 葛兰素集团有限公司 化学方法
AU2013312106B2 (en) 2012-09-10 2018-03-08 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014123889A1 (en) * 2013-02-06 2014-08-14 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
AU2014218754B2 (en) 2013-02-25 2017-04-20 VIIV Healthcare UK (No.5) Limited C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of HIV
DK3129392T3 (da) 2014-04-11 2020-10-19 Viiv Healthcare Uk No 4 Ltd Triterpenoider med hiv-modningsinhiberende aktivitet, substitueret i position 3 af en ikke-aromatisk ring som bærer en haloalkylsubstituent
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
JP2017533934A (ja) * 2014-11-14 2017-11-16 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｃ１７アリール置換ベツリン酸類似体
KR20170087478A (ko) 2014-11-14 2017-07-28 비브 헬스케어 유케이 (넘버5) 리미티드 옥소루펜 유도체
JP2018512433A (ja) 2015-04-14 2018-05-17 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド Ｈｉｖ成熟阻害剤の製造方法
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993753A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
NZ741082A (en) 2015-09-23 2023-06-30 Reata Pharmaceuticals Inc C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
EP3353158A1 (en) 2015-09-24 2018-08-01 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds with hiv maturation inhibitory activity
CN108348778A (zh) 2015-11-20 2018-07-31 Viiv保健英国第四有限公司 Hiv成熟抑制剂制剂
JP2019502728A (ja) * 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2018002849A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
CA3071992A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US11858959B2 (en) 2019-02-07 2024-01-02 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
EP3924361B1 (en) 2019-02-11 2023-09-06 Hetero Labs Limited Novel triterpene derivatives as hiv inhibitors
CA3144603C (en) 2019-07-19 2025-10-21 Reata Pharmaceuticals, Inc. C17 Polar Substitution Heteroaromatic Synthetic Triterpenoids and Their Methods of Use
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
WO2009100532A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
SI2576586T1 (sl) * 2010-06-04 2015-11-30 Bristol-Myers Squibb Company C-28 amidi derivatov modificirane c-3 betulinske kisline kot inhibitorji zorenja hiv
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Also Published As

Publication number Publication date
IL227678B (en) 2018-04-30
KR20140016279A (ko) 2014-02-07
TW201309717A (zh) 2013-03-01
EP2670765A1 (en) 2013-12-11
CA2826113C (en) 2018-09-04
KR101886467B1 (ko) 2018-08-07
CA2826113A1 (en) 2012-08-09
BR112013019419A2 (pt) 2019-12-03
AR085053A1 (es) 2013-08-07
PT2670765T (pt) 2018-01-08
US20140343000A1 (en) 2014-11-20
CN103429607A (zh) 2013-12-04
TN2013000321A1 (en) 2015-01-20
EA201391127A1 (ru) 2013-12-30
CN103429607B (zh) 2016-02-17
NZ614871A (en) 2014-06-27
SG192144A1 (en) 2013-08-30
EA022470B1 (ru) 2016-01-29
US8846647B2 (en) 2014-09-30
AU2012212509A1 (en) 2013-09-19
AU2012212509B2 (en) 2016-01-21
UY33886A (es) 2012-07-31
EP2670765B1 (en) 2017-10-18
JP6001560B2 (ja) 2016-10-05
CL2013002185A1 (es) 2013-12-27
ES2653847T3 (es) 2018-02-09
CO6751275A2 (es) 2013-09-16
US20130035318A1 (en) 2013-02-07
JP2014503595A (ja) 2014-02-13
IL227678A0 (en) 2013-09-30
MA34909B1 (fr) 2014-02-01
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
MY162186A (en) 2017-05-31
TWI628188B (zh) 2018-07-01
PH12013501528A1 (en) 2013-09-16

Similar Documents

Publication Publication Date Title
PE20141152A1 (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana
CL2019002204A1 (es) Compuestos inhibidores del vih.
CR20150454A (es) Compuestos amida para el tratamiento de vih
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO6561783A2 (es) Inhibidores del virus flaviviridae
UY35263A (es) Compuestos terapéuticos
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
DOP2014000121A (es) Derivados de betulina
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
CR20110059A (es) Compuestos organicos
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
UY32490A (es) Inhibidores de beta-secretasa
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
CR20120047A (es) Formulacion farmaceutica
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación

Legal Events

Date Code Title Description
FG Grant, registration